e-learning
resources
London 2016
Tuesday, 06.09.2016
Therapeutic trials in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC)
Jean-Paul Sculier (Brussels, Belgium), Jean-Paul Sculier, Jean-Jacques Lafitte, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Arnaud Scherpereel, Marianne Paesmans, Nathalie Leclercq, Thierry Berghmans
Source:
International Congress 2016 – Therapeutic trials in lung cancer
Session:
Therapeutic trials in lung cancer
Session type:
Oral Presentation
Number:
3345
Disease area:
Respiratory infections, Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Jean-Paul Sculier (Brussels, Belgium), Jean-Paul Sculier, Jean-Jacques Lafitte, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Arnaud Scherpereel, Marianne Paesmans, Nathalie Leclercq, Thierry Berghmans. A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC). Eur Respir J 2016; 48: Suppl. 60, 3345
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
The role of second line chemotherapy in small cell lung cancer: A retrospective analysis
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Treatment of advanced non-small cell lung cancer with trofosfamide
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Surgical treatment outcomes on early-stages of non-small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD
Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery
Year: 2015
Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy?
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Outcomes of radical treatment of early stage non-small cell lung cancer
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Lung cancer risk prediction model based on data of the SOS trial (single center non-randomized lung cancer early detection trial)
Source: International Congress 2014 – Risk assessment and tracheal reconstructions
Year: 2014
Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Pulmonary function during lung cancer therapy: A retrospective analysis of patients treated with monotherapy or multimodal treatments
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept